Table 2. Genes expression from protocol 2 (fold changes).

Groups	10 week of age				20 week of age
	E-cadherin	FSP-1	Sgk-1	NHE-1	E-cadherin	FSP-1	Sgk-1	NHE-1
DSS + NS	1.00±0.04	1.00±0.06	1.00±0.1	1.00±0.09	1.00±0.02	1.00±0.12	1.00±0.12	1.00±0.0
DSS + HS	0.52±0.30a	2.42±0.15a	2.33±0.11a	1.99±0.04a	0.41±0.02a	3.15±0.24a,#	2.99±0.10a	2.10±0.09a
DSS + HS → NS	-	-	-	-	0.48±0.03b	2.33±0.06b	2.38±0.11	1.80±0.17
DSS + HS → NS + OLM	-	-	-	-	0.73±0.05c	1.37±0.09c	1.37±0.05c	1.25±0.06c
DSS + HS → NS + AZEL	-	-	-	-	0.6±0.04	1.50±0.49c	1.35±0.79c	1.26±0.08c
DSS + HS → NS + OLM + AZEL	-	-	-	-	0.95±0.02c,d	1.10±0.02c,d	1.03±0.08c,d	0.99±0.25c
DSS + HS → NS + HYD	-	-	-	-	0.52±0.06	2.10±0.22	2.18±0.16	1.73±0.10

FSP-1; fibroblast-specific protein-1, Sgk-1; serum and glucocorticoid-regulated kinases-1, NHE-1; Na⁺/H⁺ exchanger isoform-1, DSS; Dahl salt-sensitive rats, NS; normal salt (0.5% NaCl), HS; High salt (4% NaCl), OLM; olmesartan, AZEL; azelnidipine, HYD; hydralazine. β-actin was used as an internal control and results are expressed as fold changes to 10-week values of the DSS + NS group. _# P<0.05 vs. 10-week values of the DSS + HS group. _a P<0.05 vs. DSS + NS, _b P<0.05 vs. DSS + HS, _c P<0.05 vs. DSS + HS → NS, _d P<0.05 vs. DSS + HS → NS + OLM or DSS + HS → NS + AZEL.